For more information or to provide feedback on this or any other decision support tool, email certifiedpractice@bccnp.ca

PEDIATRIC CELLULITIS

DEFINITION

An acute, diffuse, spreading infection of the skin, involving the deeper layers of the skin and the subcutaneous tissue.

Nurses with Remote Practice Certified Practice designation (RN(C)s[1]) are able to treat children with non-facial cellulitis who are **2 years of age and older.**

POTENTIAL CAUSES

- Bacteria: most commonly *Staphylococcus* species
- In B.C., methicillin resistant staph aureus comprises over 25% of staph aureus infections.

PREDISPOSING RISK FACTORS

- Local trauma (e.g., lacerations, burns, insect bites, wounds, shaving)
- Skin infections such as impetigo, scabies, furuncle, tinea pedis
- Underlying skin ulcer
- Fragile skin
- Immunocompromised host
- Diabetes
- Inflammation (e.g., eczema)
- Edema secondary to venous insufficiency or lymphedema
- Known methicillin resistant staph aureus (MRSA) positive (family or household member)

Note: If human, cat or dog bite was the original trauma, see Pediatric Bites DST

[1] RN(C) is an authorized title recommended by BCCNP that refers to BCCNP-certified RNs, and is used throughout this Decision Support Tool (DST).

BCCNP monitors and revises the BCCNP certified practice decision support tools (DSTs) every two years and as necessary based on best practices. The information provided in the DSTs is considered current as of the date of publication. BCCNP-certified nurses (RN(C)s) are responsible for ensuring they refer to the most current DSTs.

The DSTs are not intended to replace the RN(C)'s professional responsibility to exercise independent clinical judgment and use evidence to support competent, ethical care. The RN(C) must consult with or refer to a physician or nurse practitioner as appropriate, or whenever a course of action deviates from the DST.

© BCCNP June 2018/Pub. 766

TYPICAL FINDINGS OF CELLULITIS

History

- Presence of predisposing risk factor
- Area increasingly red, warm to touch, painful
- Area around skin lesion also tender but pain localized
- Edema
- Mild systemic symptoms – low-grade fever, chills, malaise, and headache may be present
- Known MRSA positive

Physical Assessment

- Local symptoms:
- Erythema and edema of area
- Warm to touch
- Possibly fluctuant (movable and compressible – fluid-based)
- May resemble peau d'orange
- Advancing edge of lesion diffuse, not sharply demarcated
- Small amount of purulent discharge may be present
- Unilateral
- Systemic indications:
- Increased temperature
- Increased pulse
- Lymphadenopathy of regional lymph nodes and / or lymphangitis

Diagnostic Tests

- Swab any wound discharge for culture and sensitivity (C&S)

MANAGEMENT AND INTERVENTIONS

Note: Do not underestimate cellulitis. It can spread very quickly and may progress rapidly to necrotizing fasciitis. It should be treated aggressively and monitored on an on-going basis.

Goals of Treatment for Mild Cellulitis

- Resolve infection
- Identify formation of abscess
- Check tetanus prophylaxis

© BCCNP June 2018/Pub. 766

Non-pharmacologic Interventions

- Apply warm or, if more comfortable, cool saline compresses to affected areas qid for 15 minutes.
- Mark border of erythema with pen to monitor spread of inflammation.
- Elevate, rest and gently splint the affected limb.

Pharmacologic Interventions

Ensure recent weight obtained for medications where dose is dependant on weight

Analgesicsacetaminophen 10-15mg/kg/dose po q4-6 hours prn Do not exceed 75mg/kg in 24 hours, from all acetaminophen sources

OR

ibuprofen 5-10mg/kg/dose po 4-6 hours prn Do not exceed 40mg/kg in 24hr

Antibiotics

Oral antibiotics if MRSA not suspected:

cephalexin 25-50 mg/kg/day po divided qid for 5-7 days

OR

- cloxacillin 50 mg/kg per day po divided qid for 5-7 days

Clients with penicillin or cephalosporin allergy (e.g. cephalexin): clindamycin 25-30 mg/kg/day po divided tid for 5-7 days

Clients with known community acquired MRSA or purulent cellulitis:

trimethoprim-sulfamethoxazole 8-12 mg/kg/day po (dosing is based on trimethoprim component) divided bid for 5-7 days

Pregnant Women (dosing as above)

- Cephalexin, cloxacillin, and acetaminophen may be used as listed above.
- DO NOT USE trimethoprim-sulfamethoxazole or ibuprofen

Breastfeeding Women (dosing as above)

- Ibuprofen can be used in breast feeding after consultation with physician or nurse practitioner.

DO NOT USE trimethoprim-sulfamethoxazole

POTENTIAL COMPLICATIONS

- Extension of infection
- Abscess formation
- Sepsis
- Necrotising fasciitis

© BCCNP June 2018/Pub. 766

- Recurrent cellulitis

CLIENT/CAREGIVER EDUCATION AND DISCHARGE INFORMATION

- Advise on condition, timeline of treatment and expected course of disease process.
- Counsel client about appropriate use of medications (dose, frequency, compliance).
- Encourage proper hygiene of all skin wounds to prevent future infection.
- Stress importance of close follow-up.
- If shaving is the cause, educate the client about shaving with the hair growth.

MONITORING AND FOLLOW-UP

- Follow-up daily to ensure that infection is controlled.
- Instruct parent or caregiver to return for reassessment immediately if lesion becomes fluctuant, if pain increases, if cellulitis spreads or if fever develops.

CONSULTATION AND/OR REFERRAL

- Consult with or refer to a physician or nurse practitioner if:
- New systemic symptoms present or progression of disease is rapid,
- no improvement after 48 hours of antibiotics,
- client is diabetic and /or immunocompromised,
- pain is out of proportion to the clinical findings,
- cellulitis is over or involves a joint, or
- any facial cellulitis.

DOCUMENTATION

As per agency policy

© BCCNP June 2018/Pub. 766

REFERENCES

More recent editions of any of the items in the Reference List may have been published since this DST was published. If you have a newer version, please use it.

Anti-Infective Review Panel. (2013). *Anti-infective guidelines for community-acquired infections*. Toronto, ON: MUMS Guideline Clearinghouse.

Blondel-Hill, E., & Fryters, S. (2012). *Bugs and drugs*: *An antimicrobial infectious diseases reference.* Edmonton, AB: Alberta Health Services.

Breen, J. O. (2010). Skin and soft tissue infections in immunocompetent patients. *American Family Physician, 81*(7), 893-899. Retrieved from http://www.aafp.org/afp/2010/0401/p893.pdf

British Columbia Centre for Disease Control. (2014). *Antimicrobial resistance trends in the province of British Columbia*. Vancouver, BC: Author.

British Columbia Centre for Disease Control. (2014). *Guidelines for the management of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)-related skin and soft tissue infections in primary care*. Vancouver, BC: Author.
British Columbia Centre for Disease Control. (2014). *Guidelines for the management of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)-related skin and soft tissue infections in primary care*. Vancouver, BC: Author.

Canadian Pharmacists Association. (2017). *Therapeutic choices*. Ottawa, ON: Author.

DynaMed. (2015, July 22). *Preseptal cellulitis.*

DynaMed. (2015, October 12). *Cellulitis.*

DynaMed. (2015, September 17). *Treatment of MRSA skin and soft tissue infections.*

DynaMed. (2015, July 22). *Orbital cellulitis.*

Esau, R. (Ed.). (2012). *British Columbia's Children's Hospital pediatric drug dosage guidelines* (6th ed.). Vancouver, BC: Children's & Women's Health Centre of B.C.

Herchline, T. E. (2017, July 05). *Cellulitis.* Retrieved from http://emedicine.medscape.com/article/214222-overview

Kim, J. & Mukovozov, I. 2017). *Toronto notes 2017: Comprehensive medical reference & review for Medical Council of Canada Qualifying Exam Part 1 and the United States Medical Licensing Exam Step 2* th 33rd. Ed.). Toronto, ON: Toronto Notes for Medical Students. Retrieved from https://www.scribd.com/document/351268506/Toronto-Notes-2017-pdf

Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J.,…Chambers, H.F. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. *Clinical Infectious Diseases,* 52(3), e18-e55.

© BCCNP June 2018/Pub. 766

Long, C. B., Madan, R. P., & Herold, B. C. (2010). Diagnosis and management of community-associated MRSA infections in children. *Expert Review of Anti-Infective Therapy, 8*(2), 183-195.

MacNeal, R. J. (2013). Description of skin lesions. Kenilworth, NJ: Merck & Co. Retrieved from http://www.merckmanuals.com/professional/dermatologic-disorders/approach-to-the-dermatologic-patient/description-of-skin-lesions

Methicillin-resistant Staphylococcus aureus in First Nations communities in Canada. (2005). *Pediatrics and Child Health, 10*(9), 557-559. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722643/pdf/pch10557.pdf

Moran, G. J., Krishnadasan, A., Gorwitz, R. J., Fosheim, G. E., McDougal, L. K., Carey, R. B., Talan, D.A. (2006). Methicillin-resistant S. aureus infections among patients in the emergency department. *New England Journal of Medicine, 355*(7), 666-674. Retrieved from http://www.nejm.org/doi/pdf/10.1056/NEJMoa055356

Napierkowski, D. (2013). Uncovering common bacterial skin infections. *Nurse Practitioner, 38*(3), 30-37. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&AuthType=cpid&custid=s5624058&db=ccm&AN=2012023989&site=ehost

NeVille-Swensen, M., & Clayton, M. (2011). Outpatient management of community-associated methicillin- resistant Staphylococcus aureus skin and soft tissue infection. *Journal of Pediatric Health Care*, 25(5), 308-315.

Rockwell, F., Goh, S. H., Al-Rawahi, G., Hoang, L., Isaac-Renton, J., Gilbert, M.,…Patrick, D. (2005). *A report on the emergence of Community-Acquired Methicillin-Resistant Staphylococcus aureus* (CA-MRSA) in British Columbia.

Stevens, D., Bisno, A. L., Chambers, H. F., Dellinger, E. P., Goldstein, E. J. C., Gorbach, S. L.,…Wade, J. C. (2014). Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases, 59*(2), e10-e52.

Watkins, J. (2012). Differentiating common bacterial skin infections. *British Journal of School Nursing, 7*(2), 77-78. Retrieved from http://search.ebscohost.com/login.aspx?direct=true&AuthType=cpid&custid=s5624058&db=ccm&AN=2011519936&site=ehost-live

Wolff, K., & Johnson, R. A. (2013). *Fitzpatrick's color atlas and synopsis of clinical dermatology* (7th ed.). New York: McGraw-Hill Medical.

© BCCNP June 2018/Pub. 766